Clinical Trial Search

Primary: Change in Visual Acuity (VA) in Participant's Study Eye — -2.8; -5.9; -8.6; -10.3 Letters read

Primary: Mean Change in Square-root Area of Geographic Atrophy (GA) From Baseline to Month 24 — 0.024; 0.050; 0.363; 0.285 mm — p=0.236

Primary: The Change in Best-corrected Visual Acuity (BCVA) From Baseline to Year 2 for All Participants. — 0.2; -11.3 ETDRS Letters

Primary: Phase I: Percentage of Participants With Adverse Events — 11; 10; 10 Participants — p=1.00

Primary: The Rate of Change From Baseline in Geographic Atrophy (GA) Lesion Area — 2.243; 2.237; 2.393 mm^2 per year — p=0.4345

Primary: Change From Baseline in the Area of Geographic Atrophy (GA) Assessed by Color Fundus Photographs (FP) in the Study Eye — -0.52; -0.94; -0.99; -0.96 square millimeter (m^2)

Primary: Growth Rate of GA Lesions, as Assessed by Fundus Autofluorescence (FAF) — 1.62; 1.87 mm2/year

Primary: Retinal Sensitivity — 12.08; 11.08; 11.45 dB — p=0.404

Primary: Difference in Square-Root Transformed GA Area Expansion Rates in the Study Eye Between the Treatment Phase and Run-in Phase Based on Fundus Autofluorescence (FAF)…

Primary: Difference in mm Squared of Cirrus HD-OCT Automated Measurements of the Illumination Areaa Under the RPE to Expert Manual Measurement of Areas of Hypofluorescence…

Primary: Least Square (LS) Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 12 — 0.26; 0.28; 0.35 mm

Primary: Number of Participants With Toxicity or Intolerable Dose Criteria — 0; 0; 0; 0 Participants

Primary: Fundus Autofluorescence Imaging to Measure the Rate of Change in Area of Geographic Atrophy — 0.41; 0.35 mm/year — p=0.39

Primary: Number of Participants With Adverse Events (AEs) — 50; 49; 129 Participants

Primary: Rate of Change in Area of Geographic Atrophy (GA) in the Study Eye at 24 Months as Compared to Baseline — 0.102 MPS DA/month

Primary: Change From Baseline in Geographic Atrophy (GA) Area, as Assessed by Fundus Autofluorescence (FAF) at Week 24 — 0.614; 1.121; 1.049; 0.911 mm^2 — p=0.0428

Primary: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 — 1.5579; 1.6512; 1.9692 mm^2 — p=0.0004

Primary: Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence — 0.292; 0.402; 0.321; 0.444 millimeters (mm) — p=0.0072

Primary: LL BCVA Score Change From Baseline — 0.7; -0.6; 1.1; -0.8 Letters

Primary: Axial Length at 36 Months — 25.28; 25.25; 25.33 mm

Primary: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 — 1.7344; 1.7563; 1.9640 mm^2 — p=0.0615

Primary: Number of Subjects With a Serious Adverse Event That, in the Opinion of the Investigator, is Related to the Study Drug — 0; 0; 0 subjects

Primary: Annualized Changes in Refractive Error (SER) — -0.70; -0.66 Dioptre/year

Primary: Visual Acuity Change From Baseline to Month 12 of the Study — 0.1; -0.05 LogMAR Unit

Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants

Primary: Change From Baseline in Size of Geographic Atrophy Lesion Area in the Study Eye — 6.219; 6.897; 5.526; 0.898 Disc Area

Primary: Change in Macular Drusen Volume — 0.05; 0.11; 20.0; 9.0 mm^3

Primary: Treatment Group Comparison of Change in Spherical Equivalent Refractive Error. — 0; 0; 1; 0 Participants

Primary: Rod Sensitivity Within the Central Retina as Measured on the Nidek MP-3S — 7; 20 Participants — p=<0.05

Primary: Corneal Thickness — 542.23; 546.16; 544.32 microns